Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
- To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.
To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) for each treatment arm.
To evaluate blinded independent central review (BICR) assessed or investigator assessed objective response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by treatment arm and by mismatch repair (MMR) immunohistochemistry (IHC) status in patients who enter the study with measurable disease.
To evaluate BICR assessed or investigator assessed duration of response (DOR) by treatment arm and by MMR IHC status in patients who enter the study with measurable disease.
To evaluate the effect of pembrolizumab (MK-3475) on overall survival (OS) in patients with mismatch repair protein proficient (pMMR) or mismatch repair deficiency (dMMR).
To determine whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with improved patient reported physical function as measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-physical function scale (short form), quality of life as measured with the Functional Assessment of Cancer Therapy (FACT) - Endometrial Trial Outcome Index (En TOI) and worsened fatigue as measured with the PROMIS-Fatigue scale (short form) in the pMMR patients.
To determine concordance between institutional MMR immunohistochemistry (IHC) testing and centralized MMR IHC.
To explore the correlation between patient-reported physical function as measured with the PROMIS-physical function scale (short form) and quality of life as measure with the FACT-En TOI.
To explore whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with self-reported neurotoxicity as measured with the FACT/Gynecologic Oncology Group Neurotoxicity (GOG-Ntx) subscale (short) and the extent to which patients differ on their self-reported bother from side effects of cancer therapy in the pMMR patients.
To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer by Programmed Death Ligand 1 (PD-L1) IHC (positive versus [vs] negative).
To assess the association between PD-L1 IHC (positive vs negative) and mismatch repair status (pMMR and dMMR).
OUTLINE: Patients are randomized to 1 of 2 arms.
COMBINATION PHASE: Patients receive placebo intravenously (IV) over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease may continue treatment for up to a total 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Arms and Interventions
|Active Comparator: Arm I (placebo, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
Other: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
|Experimental: Arm II (pembrolizumab, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Primary Outcome Measures
- Progression-free survival (PFS) [Duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years]
Will be tested with a stratified log-rank statistic.
Secondary Outcome Measures
- Incidence of adverse events [5 years]
Assessed by Common Terminology Criteria for Adverse Events (CTCAE). Toxicities will be screened for differences between treatments by using an exact method or a Chi-Square test. For a given adverse event, each patient will be graded according to the worse grade experienced while on therapy (and within 30 days of treatment). These toxicities will then be divided into two or three categories such as mild, moderate, and severe or mild to moderate versus severe. The rates of severe toxicities may be characterized by risk ratios or odds ratios with confidence intervals (unadjusted for multiplicity). The number of toxicities examined is usually fairly large, so these analyses will be considered exploratory and may be inspected in light of other studies.
- Objective tumor response [5 years]
Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1.
- Duration of objective response [5 years]
The time difference between the dates of first response and first progression; patients who do not progress are considered censored.
- Overall survival (OS) [Time from study entry to time of death or the date of last contact, assessed up to 5 years]
- Quality of life (QoL) and patient-reported outcomes (PROs) [5 years]
Measured by the Function Assessment of Cancer Therapy (FACT)-Endometrial Trial Outcome Index (En-TOI), the FACT/Gynecologic Oncology Group (GOG)-Neurotoxicity (Ntx) subscale (short), Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue (short form),the PROMIS-physical function (short form) and a single-item measuring bother from side effects of cancer therapy. A linear mixed model for repeated measures will be used to estimate and compare the mean differences between the treatment groups. Model covariates will include the patients' randomly assigned study treatment, age at enrollment onto the study, pre-treatment quality of life/patient reported outcome score, assessment time and treatment-by-time interaction. The stratification factors will be the same factors included in the clinical primary analysis. Hochberg's step-up multiple testing procedure (Hochberg, 1988) will be used to adjust p-values for each assessment time points estimated from the fitted model.
- Incidence of pembrolizumab treatment and self-reported neurotoxicity [5 years]
Assessed with FACT/GOG-Ntx.
- Concordance between Institutional Mismatch repair (MMR) immunohistochemistry (IHC) testing and centralized MMR IHC [5 years]
Concordance between institutional MMR IHC testing and centralized MMR IHC. The patient's MMR IHC status will be assessed for prognostic value by conducting stratified log-rank tests or Cox Proportional Hazards (PH) modeling when assessing the impact on PFS or OS. When assessing the impact on the probability of response, a logistic regression model will be considered and include other pertinent variables that may influence response. A Cox PH model will be used to assess predictive value of MMR IHC status for regimen efficacy through an interaction term. A similar type of analysis may be attempted with response using logistic regression. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics such as kappa statistics (e.g. Cohen's kappa coefficient).
- Effect of pembrolizumab on PFS and OS by Program Death Ligand 1 (PD-L1) IHC [5 years]
Will assess the effect of pembrolizumab on PFS and OS by PD-L1 (combined positive score [CPS]) within proficient MMR (pMMR) and deficient MMR (dMMR) populations. The effectiveness of pembrolizumab will be compared by PD-L1 status (CPS). A formal test will be conducted by examining the interaction term between pembrolizumab treatment (yes or no) with PD-L1 status. The association between PD-L1 CPS status and MMR IHC status will be assessed with odds ratios. A test may be conducted with a Fisher's Exact Test, and confidence intervals will be provided.
- Association between PD-L1 IHC and MMR status [5 years]
Measures of association between PD-L1 IHC (CPS) and MMR IHC status. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics such as kappa statistics (e.g. Cohen's kappa coefficient).
Measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.
Pathology report showing results of institutional MMR IHC testing.
Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.).
Submission of tumor specimens for centralized MMR IHC testing is required after Step 1 and before Step 2 registration.
In patients with measurable disease, lesions will be defined and monitored by RECIST version (v) 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.
Patients may have received
NO prior chemotherapy for treatment of endometrial cancer OR
Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) provided adjuvant chemotherapy was completed >= 12 months prior to STEP 2 registration.
Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to STEP 2 registration.
Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to STEP 2 registration.
Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted.
Age >= 18
Performance status of 0, 1 or 2.
Platelets >= 100,000/mcl.
Absolute neutrophil count (ANC) >= 1,500/mcl.
Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN).
Total serum bilirubin level =< 1.5 x upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled).
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN.
Thyroid stimulating hormone (TSH) within normal limits. If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal Free T4 level is required.
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of Step 2 registration are eligible for this trial.
For patients of child bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
Administration of study drugs (pembrolizumab [MK-3475], paclitaxel, carboplatin) may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from at least 14 days prior to Step 2 registration (for oral contraceptives), during treatment, and for 120 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:
Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to Step 2 registration; OR
Have a congenital or acquired condition that prevents childbearing.
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.
Patients with prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.
Patients who have a history of a severe hypersensitivity reaction to monoclonal antibody or pembrolizumab (MK-3475) and/or its excipients; and/or a severe hypersensitivity reaction to paclitaxel and/or carboplatin
Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to Step 2 registration.
Patients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Step 2 registration.
Patients who have received steroids as CT scan contrast premedication may be enrolled.
The use of inhaled or topical corticosteroids is allowed.
The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to Step 2 registration and remain clinically stable.
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease.
Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.
Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.
Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; and cirrhosis.
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
Pregnant or lactating patients.
Contacts and Locations
|1||University of Alabama at Birmingham Cancer Center||Birmingham||Alabama||United States||35233|
|2||Alaska Women's Cancer Care||Anchorage||Alaska||United States||99508|
|3||CTCA at Western Regional Medical Center||Goodyear||Arizona||United States||85338|
|4||NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro||Jonesboro||Arkansas||United States||72401|
|5||University of Arkansas for Medical Sciences||Little Rock||Arkansas||United States||72205|
|6||Kaiser Permanente-Baldwin Park||Baldwin Park||California||United States||91706|
|7||Kaiser Permanente-Bellflower||Bellflower||California||United States||90706|
|8||Alta Bates Summit Medical Center-Herrick Campus||Berkeley||California||United States||94704|
|9||Community Cancer Institute||Clovis||California||United States||93611|
|10||City of Hope Comprehensive Cancer Center||Duarte||California||United States||91010|
|11||Kaiser Permanente - Harbor City||Harbor City||California||United States||90710|
|12||Kaiser Permanente-Irvine||Irvine||California||United States||92618|
|13||UC San Diego Moores Cancer Center||La Jolla||California||United States||92093|
|14||City of Hope Antelope Valley||Lancaster||California||United States||93534|
|15||Kaiser Permanente Los Angeles Medical Center||Los Angeles||California||United States||90027|
|16||Los Angeles County-USC Medical Center||Los Angeles||California||United States||90033|
|17||USC / Norris Comprehensive Cancer Center||Los Angeles||California||United States||90033|
|18||Cedars Sinai Medical Center||Los Angeles||California||United States||90048|
|19||UCLA / Jonsson Comprehensive Cancer Center||Los Angeles||California||United States||90095|
|20||Palo Alto Medical Foundation-Gynecologic Oncology||Mountain View||California||United States||94040|
|21||Kaiser Permanente-Oakland||Oakland||California||United States||94611|
|22||Saint Joseph Hospital - Orange||Orange||California||United States||92868|
|23||UC Irvine Health/Chao Family Comprehensive Cancer Center||Orange||California||United States||92868|
|24||Eisenhower Medical Center||Rancho Mirage||California||United States||92270|
|25||Mercy Regional Cancer Center||Redding||California||United States||96001|
|26||Mercy Oncology Center||Redding||California||United States||96002|
|27||Kaiser Permanente-Riverside||Riverside||California||United States||92505|
|28||Kaiser Permanente-Roseville||Roseville||California||United States||95661|
|29||Kaiser Permanente Downtown Commons||Sacramento||California||United States||95814|
|30||Mercy Cancer Center - Sacramento||Sacramento||California||United States||95816|
|31||Kaiser Permanente-San Diego Zion||San Diego||California||United States||92120|
|32||Naval Medical Center -San Diego||San Diego||California||United States||92134|
|33||Zuckerberg San Francisco General Hospital||San Francisco||California||United States||94110|
|34||California Pacific Medical Center-Pacific Campus||San Francisco||California||United States||94115|
|35||Kaiser Permanente-San Francisco||San Francisco||California||United States||94115|
|36||UCSF Medical Center-Mission Bay||San Francisco||California||United States||94158|
|37||Kaiser Permanente-Santa Teresa-San Jose||San Jose||California||United States||95119|
|38||Kaiser Permanente San Leandro||San Leandro||California||United States||94577|
|39||Kaiser Permanente-San Marcos||San Marcos||California||United States||92078|
|40||Kaiser Permanente Medical Center - Santa Clara||Santa Clara||California||United States||95051|
|41||City of Hope South Pasadena||South Pasadena||California||United States||91030|
|42||Kaiser Permanente-South San Francisco||South San Francisco||California||United States||94080|
|43||Palo Alto Medical Foundation-Sunnyvale||Sunnyvale||California||United States||94086|
|44||City of Hope Upland||Upland||California||United States||91786|
|45||Kaiser Permanente-Vallejo||Vallejo||California||United States||94589|
|46||Kaiser Permanente-Walnut Creek||Walnut Creek||California||United States||94596|
|47||John Muir Medical Center-Walnut Creek||Walnut Creek||California||United States||94598|
|48||Penrose-Saint Francis Healthcare||Colorado Springs||Colorado||United States||80907|
|49||UCHealth Memorial Hospital Central||Colorado Springs||Colorado||United States||80909|
|50||Memorial Hospital North||Colorado Springs||Colorado||United States||80920|
|51||Poudre Valley Hospital||Fort Collins||Colorado||United States||80524|
|52||Cancer Care and Hematology-Fort Collins||Fort Collins||Colorado||United States||80528|
|53||North Colorado Medical Center||Greeley||Colorado||United States||80631|
|54||UCHealth Greeley Hospital||Greeley||Colorado||United States||80631|
|55||Medical Center of the Rockies||Loveland||Colorado||United States||80538|
|56||McKee Medical Center||Loveland||Colorado||United States||80539|
|57||Danbury Hospital||Danbury||Connecticut||United States||06810|
|58||Smilow Cancer Hospital Care Center - Guiford||Guilford||Connecticut||United States||06437|
|59||Hartford Hospital||Hartford||Connecticut||United States||06102|
|60||Smilow Cancer Hospital Care Center at Saint Francis||Hartford||Connecticut||United States||06105|
|61||The Hospital of Central Connecticut||New Britain||Connecticut||United States||06050|
|62||Yale University||New Haven||Connecticut||United States||06520|
|63||Yale-New Haven Hospital North Haven Medical Center||North Haven||Connecticut||United States||06473|
|64||Norwalk Hospital||Norwalk||Connecticut||United States||06856|
|65||Stamford Hospital/Bennett Cancer Center||Stamford||Connecticut||United States||06904|
|66||Smilow Cancer Hospital-Torrington Care Center||Torrington||Connecticut||United States||06790|
|67||Smilow Cancer Hospital Care Center-Trumbull||Trumbull||Connecticut||United States||06611|
|68||Smilow Cancer Hospital-Waterbury Care Center||Waterbury||Connecticut||United States||06708|
|69||Smilow Cancer Hospital Care Center - Waterford||Waterford||Connecticut||United States||06385|
|70||Helen F Graham Cancer Center||Newark||Delaware||United States||19713|
|71||MedStar Washington Hospital Center||Washington||District of Columbia||United States||20010|
|72||Sibley Memorial Hospital||Washington||District of Columbia||United States||20016|
|73||Florida Cancer Specialists - Bradenton||Bradenton||Florida||United States||34209|
|74||Florida Cancer Specialists - Sarasota||Sarasota||Florida||United States||34232|
|75||Florida Cancer Specialists - Sarasota Downtown||Sarasota||Florida||United States||34236|
|76||Sarasota Memorial Hospital||Sarasota||Florida||United States||34239|
|77||Florida Cancer Specialists - Venice Island||Venice||Florida||United States||34285|
|78||Florida Cancer Specialists - Venice Healthpark||Venice||Florida||United States||34292|
|79||Grady Health System||Atlanta||Georgia||United States||30303|
|80||Emory University Hospital Midtown||Atlanta||Georgia||United States||30308|
|81||Emory University Hospital/Winship Cancer Institute||Atlanta||Georgia||United States||30322|
|82||Emory Saint Joseph's Hospital||Atlanta||Georgia||United States||30342|
|83||Northside Hospital||Atlanta||Georgia||United States||30342|
|84||WellStar Cobb Hospital||Austell||Georgia||United States||30106|
|85||Piedmont Fayette Hospital||Fayetteville||Georgia||United States||30214|
|86||Northeast Georgia Medical Center-Gainesville||Gainesville||Georgia||United States||30501|
|87||WellStar Health System Inc||Marietta||Georgia||United States||30060|
|88||Wellstar Kennestone Hospital||Marietta||Georgia||United States||30060|
|89||CTCA at Southeastern Regional Medical Center||Newnan||Georgia||United States||30265|
|90||WellStar North Fulton Hospital||Roswell||Georgia||United States||30076|
|91||Memorial Health University Medical Center||Savannah||Georgia||United States||31404|
|92||Lewis Cancer and Research Pavilion at Saint Joseph's/Candler||Savannah||Georgia||United States||31405|
|93||WellStar Vinings Health Park||Smyrna||Georgia||United States||30080|
|94||Queen's Medical Center||Honolulu||Hawaii||United States||96813|
|95||Kapiolani Medical Center for Women and Children||Honolulu||Hawaii||United States||96826|
|96||Saint Alphonsus Cancer Care Center-Boise||Boise||Idaho||United States||83706|
|97||Saint Luke's Cancer Institute - Boise||Boise||Idaho||United States||83712|
|98||Saint Alphonsus Cancer Care Center-Caldwell||Caldwell||Idaho||United States||83605|
|99||Saint Luke's Cancer Institute - Fruitland||Fruitland||Idaho||United States||83619|
|100||Saint Luke's Cancer Institute - Meridian||Meridian||Idaho||United States||83642|
|101||Saint Alphonsus Medical Center-Nampa||Nampa||Idaho||United States||83686|
|102||Saint Luke's Cancer Institute - Nampa||Nampa||Idaho||United States||83686|
|103||Saint Luke's Cancer Institute - Twin Falls||Twin Falls||Idaho||United States||83301|
|104||Northwestern University||Chicago||Illinois||United States||60611|
|105||Rush University Medical Center||Chicago||Illinois||United States||60612|
|106||University of Illinois||Chicago||Illinois||United States||60612|
|107||University of Chicago Comprehensive Cancer Center||Chicago||Illinois||United States||60637|
|108||Carle on Vermilion||Danville||Illinois||United States||61832|
|109||Cancer Care Specialists of Illinois - Decatur||Decatur||Illinois||United States||62526|
|110||Crossroads Cancer Center||Effingham||Illinois||United States||62401|
|111||NorthShore University HealthSystem-Evanston Hospital||Evanston||Illinois||United States||60201|
|112||Northwestern Medicine Cancer Center Delnor||Geneva||Illinois||United States||60134|
|113||NorthShore University HealthSystem-Glenbrook Hospital||Glenview||Illinois||United States||60026|
|114||Ingalls Memorial Hospital||Harvey||Illinois||United States||60426|
|115||NorthShore University HealthSystem-Highland Park Hospital||Highland Park||Illinois||United States||60035|
|116||Carle Physician Group-Mattoon/Charleston||Mattoon||Illinois||United States||61938|
|117||Loyola University Medical Center||Maywood||Illinois||United States||60153|
|118||UC Comprehensive Cancer Center at Silver Cross||New Lenox||Illinois||United States||60451|
|119||Cancer Care Center of O'Fallon||O'Fallon||Illinois||United States||62269|
|120||University of Chicago Medicine-Orland Park||Orland Park||Illinois||United States||60462|
|121||Springfield Clinic||Springfield||Illinois||United States||62702|
|122||Carle Cancer Center||Urbana||Illinois||United States||61801|
|123||Northwestern Medicine Cancer Center Warrenville||Warrenville||Illinois||United States||60555|
|124||Midwestern Regional Medical Center||Zion||Illinois||United States||60099|
|125||Northwest Cancer Center - Main Campus||Crown Point||Indiana||United States||46307|
|126||Northwest Oncology LLC||Dyer||Indiana||United States||46311|
|127||Northwest Cancer Center - Hobart||Hobart||Indiana||United States||46342|
|128||Saint Mary Medical Center||Hobart||Indiana||United States||46342|
|129||Indiana University/Melvin and Bren Simon Cancer Center||Indianapolis||Indiana||United States||46202|
|130||Community Cancer Center East||Indianapolis||Indiana||United States||46219|
|131||Community Cancer Center South||Indianapolis||Indiana||United States||46227|
|132||Franciscan Health Indianapolis||Indianapolis||Indiana||United States||46237|
|133||Community Cancer Center North||Indianapolis||Indiana||United States||46256|
|134||Saint Vincent Hospital and Health Care Center||Indianapolis||Indiana||United States||46260|
|135||Saint Catherine Hospital||Indianapolis||Indiana||United States||46312|
|136||Franciscan Health Mooresville||Mooresville||Indiana||United States||46158|
|137||The Community Hospital||Munster||Indiana||United States||46321|
|138||Women's Diagnostic Center - Munster||Munster||Indiana||United States||46321|
|139||Northwest Cancer Center - Valparaiso||Valparaiso||Indiana||United States||46383|
|140||University of Iowa/Holden Comprehensive Cancer Center||Iowa City||Iowa||United States||52242|
|141||University of Kansas Clinical Research Center||Fairway||Kansas||United States||66205|
|142||University of Kansas Cancer Center||Kansas City||Kansas||United States||66160|
|143||University of Kansas Hospital-Westwood Cancer Center||Westwood||Kansas||United States||66205|
|144||Saint Elizabeth Healthcare Edgewood||Edgewood||Kentucky||United States||41017|
|145||LSU Health Baton Rouge-North Clinic||Baton Rouge||Louisiana||United States||70805|
|146||Our Lady of the Lake Physicians Group - Medical Oncology||Baton Rouge||Louisiana||United States||70809|
|147||Our Lady of the Lake Medical Oncology||Baton Rouge||Louisiana||United States||70817|
|148||Woman's Hospital||Baton Rouge||Louisiana||United States||70817|
|149||East Jefferson General Hospital||Metairie||Louisiana||United States||70006|
|150||University Medical Center New Orleans||New Orleans||Louisiana||United States||70112|
|151||Ochsner Baptist Medical Center||New Orleans||Louisiana||United States||70115|
|152||Ochsner Medical Center Jefferson||New Orleans||Louisiana||United States||70121|
|153||Harold Alfond Center for Cancer Care||Augusta||Maine||United States||04330|
|154||Waldo County General Hospital||Belfast||Maine||United States||04915|
|155||MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford||Biddeford||Maine||United States||04005|
|156||Lafayette Family Cancer Center-EMMC||Brewer||Maine||United States||04412|
|157||Penobscot Bay Medical Center||Rockport||Maine||United States||04856|
|158||MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford||Sanford||Maine||United States||04073|
|159||Maine Medical Center- Scarborough Campus||Scarborough||Maine||United States||04074|
|160||Anne Arundel Medical Center||Annapolis||Maryland||United States||21401|
|161||University of Maryland/Greenebaum Cancer Center||Baltimore||Maryland||United States||21201|
|162||Greater Baltimore Medical Center||Baltimore||Maryland||United States||21204|
|163||Sinai Hospital of Baltimore||Baltimore||Maryland||United States||21215|
|164||Saint Agnes Hospital||Baltimore||Maryland||United States||21229|
|165||MedStar Franklin Square Medical Center/Weinberg Cancer Institute||Baltimore||Maryland||United States||21237|
|166||Johns Hopkins University/Sidney Kimmel Cancer Center||Baltimore||Maryland||United States||21287|
|167||UM Upper Chesapeake Medical Center||Bel Air||Maryland||United States||21014|
|168||Walter Reed National Military Medical Center||Bethesda||Maryland||United States||20889-5600|
|169||University of Maryland Shore Medical Center at Easton||Easton||Maryland||United States||21601|
|170||Lahey Hospital and Medical Center||Burlington||Massachusetts||United States||01805|
|171||Lowell General Hospital||Lowell||Massachusetts||United States||01854|
|172||Baystate Medical Center||Springfield||Massachusetts||United States||01199|
|173||Winchester Hospital||Winchester||Massachusetts||United States||01890|
|174||UMass Memorial Medical Center - Memorial Division||Worcester||Massachusetts||United States||01605|
|175||Saint Joseph Mercy Hospital||Ann Arbor||Michigan||United States||48106|
|176||University of Michigan Comprehensive Cancer Center||Ann Arbor||Michigan||United States||48109|
|177||Genesee Cancer and Blood Disease Treatment Center||Flint||Michigan||United States||48503|
|178||Genesee Hematology Oncology PC||Flint||Michigan||United States||48503|
|179||Genesys Hurley Cancer Institute||Flint||Michigan||United States||48503|
|180||Spectrum Health at Butterworth Campus||Grand Rapids||Michigan||United States||49503|
|181||Bronson Methodist Hospital||Kalamazoo||Michigan||United States||49007|
|182||West Michigan Cancer Center||Kalamazoo||Michigan||United States||49007|
|183||Sparrow Hospital||Lansing||Michigan||United States||48912|
|184||Munson Medical Center||Traverse City||Michigan||United States||49684|
|185||Sanford Joe Lueken Cancer Center||Bemidji||Minnesota||United States||56601|
|186||Essentia Health Cancer Center||Duluth||Minnesota||United States||55805|
|187||Mayo Clinic in Rochester||Rochester||Minnesota||United States||55905|
|188||Mississippi Baptist Medical Center||Jackson||Mississippi||United States||39202|
|189||University of Mississippi Medical Center||Jackson||Mississippi||United States||39216|
|190||Saint Luke's Hospital of Kansas City||Kansas City||Missouri||United States||64111|
|191||Washington University School of Medicine||Saint Louis||Missouri||United States||63110|
|192||Mercy Hospital Saint Louis||Saint Louis||Missouri||United States||63141|
|193||Mercy Hospital Springfield||Springfield||Missouri||United States||65804|
|194||Community Hospital of Anaconda||Anaconda||Montana||United States||59711|
|195||Billings Clinic Cancer Center||Billings||Montana||United States||59101|
|196||CHI Health Saint Francis||Grand Island||Nebraska||United States||68803|
|197||Nebraska Methodist Hospital||Omaha||Nebraska||United States||68114|
|198||University of Nebraska Medical Center||Omaha||Nebraska||United States||68198|
|199||Memorial Sloan Kettering Basking Ridge||Basking Ridge||New Jersey||United States||07920|
|200||Monmouth Medical Center Southern Campus||Lakewood||New Jersey||United States||08701|
|201||Saint Barnabas Medical Center||Livingston||New Jersey||United States||07039|
|202||Monmouth Medical Center||Long Branch||New Jersey||United States||07740|
|203||Memorial Sloan Kettering Monmouth||Middletown||New Jersey||United States||07748|
|204||Memorial Sloan Kettering Bergen||Montvale||New Jersey||United States||07645|
|205||Jersey Shore Medical Center||Neptune||New Jersey||United States||07753|
|206||Rutgers Cancer Institute of New Jersey||New Brunswick||New Jersey||United States||08903|
|207||The Valley Hospital-Luckow Pavilion||Paramus||New Jersey||United States||07652|
|208||Neurosurgeons of New Jersey-Ridgewood||Ridgewood||New Jersey||United States||07450|
|209||Valley Hospital||Ridgewood||New Jersey||United States||07450|
|210||Robert Wood Johnson University Hospital Somerset||Somerville||New Jersey||United States||08876|
|211||Community Medical Center||Toms River||New Jersey||United States||08755|
|212||Valley Medical Group - Wayne Multispecialty Practice||Wayne||New Jersey||United States||07470|
|213||Valley Health System-Hematology/Oncology||Westwood||New Jersey||United States||07675|
|214||University of New Mexico Cancer Center||Albuquerque||New Mexico||United States||87102|
|215||Southwest Gynecologic Oncology Associates Inc||Albuquerque||New Mexico||United States||87106|
|216||Northwell Health Imbert Cancer Center||Bay Shore||New York||United States||11706|
|217||Island Gynecologic Oncology||Brightwaters||New York||United States||11718|
|218||Montefiore Medical Center-Einstein Campus||Bronx||New York||United States||10461|
|219||Montefiore Medical Center - Moses Campus||Bronx||New York||United States||10467|
|220||New York-Presbyterian/Brooklyn Methodist Hospital||Brooklyn||New York||United States||11215|
|221||Roswell Park Cancer Institute||Buffalo||New York||United States||14263|
|222||Memorial Sloan Kettering Commack||Commack||New York||United States||11725|
|223||The New York Hospital Medical Center of Queens||Flushing||New York||United States||11355|
|224||Memorial Sloan Kettering Westchester||Harrison||New York||United States||10604|
|225||Northwell Health/Center for Advanced Medicine||Lake Success||New York||United States||11042|
|226||NYU Winthrop Hospital||Mineola||New York||United States||11501|
|227||Laura and Isaac Perlmutter Cancer Center at NYU Langone||New York||New York||United States||10016|
|228||NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center||New York||New York||United States||10032|
|229||Memorial Sloan Kettering Cancer Center||New York||New York||United States||10065|
|230||NYP/Weill Cornell Medical Center||New York||New York||United States||10065|
|231||Highland Hospital||Rochester||New York||United States||14620|
|232||University of Rochester||Rochester||New York||United States||14642|
|233||Staten Island University Hospital||Staten Island||New York||United States||10305|
|234||Stony Brook University Medical Center||Stony Brook||New York||United States||11794|
|235||State University of New York Upstate Medical University||Syracuse||New York||United States||13210|
|236||Memorial Sloan Kettering Nassau||Uniondale||New York||United States||11553|
|237||UNC Lineberger Comprehensive Cancer Center||Chapel Hill||North Carolina||United States||27599|
|238||Carolinas Medical Center/Levine Cancer Institute||Charlotte||North Carolina||United States||28203|
|239||Southeastern Medical Oncology Center-Clinton||Clinton||North Carolina||United States||28328|
|240||Atrium Health Cabarrus/LCI-Concord||Concord||North Carolina||United States||28025|
|241||Southeastern Medical Oncology Center-Goldsboro||Goldsboro||North Carolina||United States||27534|
|242||Margaret R Pardee Memorial Hospital||Hendersonville||North Carolina||United States||28791|
|243||Southeastern Medical Oncology Center-Jacksonville||Jacksonville||North Carolina||United States||28546|
|244||New Hanover Regional Medical Center/Zimmer Cancer Center||Wilmington||North Carolina||United States||28401|
|245||Wake Forest University Health Sciences||Winston-Salem||North Carolina||United States||27157|
|246||Sanford Bismarck Medical Center||Bismarck||North Dakota||United States||58501|
|247||Sanford Broadway Medical Center||Fargo||North Dakota||United States||58122|
|248||Sanford Roger Maris Cancer Center||Fargo||North Dakota||United States||58122|
|249||Summa Health System - Akron Campus||Akron||Ohio||United States||44304|
|250||UHHS-Chagrin Highlands Medical Center||Beachwood||Ohio||United States||44122|
|251||Aultman Health Foundation||Canton||Ohio||United States||44710|
|252||Geauga Hospital||Chardon||Ohio||United States||44024|
|253||University of Cincinnati Cancer Center-UC Medical Center||Cincinnati||Ohio||United States||45219|
|254||Good Samaritan Hospital - Cincinnati||Cincinnati||Ohio||United States||45220|
|255||Case Western Reserve University||Cleveland||Ohio||United States||44106|
|256||MetroHealth Medical Center||Cleveland||Ohio||United States||44109|
|257||Cleveland Clinic Cancer Center/Fairview Hospital||Cleveland||Ohio||United States||44111|
|258||Cleveland Clinic Foundation||Cleveland||Ohio||United States||44195|
|259||Ohio State University Comprehensive Cancer Center||Columbus||Ohio||United States||43210|
|260||Riverside Methodist Hospital||Columbus||Ohio||United States||43214|
|261||The Mark H Zangmeister Center||Columbus||Ohio||United States||43219|
|262||Hillcrest Hospital Cancer Center||Mayfield Heights||Ohio||United States||44124|
|263||UH Seidman Cancer Center at Lake Health Mentor Campus||Mentor||Ohio||United States||44060|
|264||ProMedica Flower Hospital||Sylvania||Ohio||United States||43560|
|265||University of Cincinnati Cancer Center-West Chester||West Chester||Ohio||United States||45069|
|266||UH Seidman Cancer Center at Saint John Medical Center||Westlake||Ohio||United States||44145|
|267||University of Oklahoma Health Sciences Center||Oklahoma City||Oklahoma||United States||73104|
|268||Oklahoma Cancer Specialists and Research Institute-Tulsa||Tulsa||Oklahoma||United States||74146|
|269||Saint Charles Health System||Bend||Oregon||United States||97701|
|270||Saint Alphonsus Medical Center-Ontario||Ontario||Oregon||United States||97914|
|271||Legacy Good Samaritan Hospital and Medical Center||Portland||Oregon||United States||97210|
|272||Providence Portland Medical Center||Portland||Oregon||United States||97213|
|273||Providence Saint Vincent Medical Center||Portland||Oregon||United States||97225|
|274||Legacy Meridian Park Hospital||Tualatin||Oregon||United States||97062|
|275||Lehigh Valley Hospital-Cedar Crest||Allentown||Pennsylvania||United States||18103|
|276||Lehigh Valley Hospital - Muhlenberg||Bethlehem||Pennsylvania||United States||18017|
|277||Geisinger Medical Center||Danville||Pennsylvania||United States||17822|
|278||Ephrata Cancer Center||Ephrata||Pennsylvania||United States||17522|
|279||Adams Cancer Center||Gettysburg||Pennsylvania||United States||17325|
|280||Cherry Tree Cancer Center||Hanover||Pennsylvania||United States||17331|
|281||Jefferson Hospital||Jefferson Hills||Pennsylvania||United States||15025|
|282||Lancaster General Ann B Barshinger Cancer Institute||Lancaster||Pennsylvania||United States||17601|
|283||Lancaster General Hospital||Lancaster||Pennsylvania||United States||17602|
|284||Sechler Family Cancer Center||Lebanon||Pennsylvania||United States||17042|
|285||Forbes Hospital||Monroeville||Pennsylvania||United States||15146|
|286||UPMC Hillman Cancer Center - Monroeville||Monroeville||Pennsylvania||United States||15146|
|287||Thomas Jefferson University Hospital||Philadelphia||Pennsylvania||United States||19107|
|288||UPMC-Magee Womens Hospital||Pittsburgh||Pennsylvania||United States||15213|
|289||West Penn Hospital||Pittsburgh||Pennsylvania||United States||15224|
|290||University of Pittsburgh Cancer Institute (UPCI)||Pittsburgh||Pennsylvania||United States||15232|
|291||Geisinger Cancer Services-Pottsville||Pottsville||Pennsylvania||United States||17901|
|292||Reading Hospital||West Reading||Pennsylvania||United States||19611|
|293||Wexford Health and Wellness Pavilion||Wexford||Pennsylvania||United States||15090|
|294||Geisinger Wyoming Valley/Henry Cancer Center||Wilkes-Barre||Pennsylvania||United States||18711|
|295||Asplundh Cancer Pavilion||Willow Grove||Pennsylvania||United States||19090|
|296||WellSpan Health-York Cancer Center||York||Pennsylvania||United States||17403|
|297||WellSpan Health-York Hospital||York||Pennsylvania||United States||17403|
|298||Women and Infants Hospital||Providence||Rhode Island||United States||02905|
|299||Medical University of South Carolina||Charleston||South Carolina||United States||29425|
|300||Saint Francis Hospital||Greenville||South Carolina||United States||29601|
|301||Prisma Health Cancer Institute - Faris||Greenville||South Carolina||United States||29605|
|302||Saint Francis Cancer Center||Greenville||South Carolina||United States||29607|
|303||Prisma Health Cancer Institute - Seneca||Seneca||South Carolina||United States||29672|
|304||Rapid City Regional Hospital||Rapid City||South Dakota||United States||57701|
|305||Sanford Cancer Center Oncology Clinic||Sioux Falls||South Dakota||United States||57104|
|306||Avera Cancer Institute||Sioux Falls||South Dakota||United States||57105|
|307||Baptist Memorial Hospital and Cancer Center-Memphis||Memphis||Tennessee||United States||38120|
|308||Vanderbilt University/Ingram Cancer Center||Nashville||Tennessee||United States||37232|
|309||Parkland Memorial Hospital||Dallas||Texas||United States||75235|
|310||UT Southwestern/Simmons Cancer Center-Dallas||Dallas||Texas||United States||75390|
|311||Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center||Houston||Texas||United States||77030|
|312||Ben Taub General Hospital||Houston||Texas||United States||77030|
|313||Houston Methodist Hospital||Houston||Texas||United States||77030|
|314||Methodist Willowbrook Hospital||Houston||Texas||United States||77070|
|315||Houston Methodist Sugar Land Hospital||Sugar Land||Texas||United States||77479|
|316||Houston Methodist The Woodlands Hospital||The Woodlands||Texas||United States||77385|
|317||University of Utah Sugarhouse Health Center||Salt Lake City||Utah||United States||84106|
|318||Huntsman Cancer Institute/University of Utah||Salt Lake City||Utah||United States||84112|
|319||University of Vermont Medical Center||Burlington||Vermont||United States||05401|
|320||University of Virginia Cancer Center||Charlottesville||Virginia||United States||22908|
|321||Virginia Commonwealth University/Massey Cancer Center||Richmond||Virginia||United States||23298|
|322||MultiCare Gig Harbor Medical Park||Gig Harbor||Washington||United States||98335|
|323||Kadlec Clinic Hematology and Oncology||Kennewick||Washington||United States||99336|
|324||MultiCare Good Samaritan Hospital||Puyallup||Washington||United States||98372|
|325||Valley Medical Center||Renton||Washington||United States||98055|
|326||Swedish Medical Center-First Hill||Seattle||Washington||United States||98122-4307|
|327||MultiCare Tacoma General Hospital||Tacoma||Washington||United States||98405|
|328||Legacy Salmon Creek Hospital||Vancouver||Washington||United States||98686|
|329||West Virginia University Charleston Division||Charleston||West Virginia||United States||25304|
|330||Monongalia Hospital||Morgantown||West Virginia||United States||26505|
|331||West Virginia University Healthcare||Morgantown||West Virginia||United States||26506|
|332||Aurora Cancer Care-Southern Lakes VLCC||Burlington||Wisconsin||United States||53105|
|333||Marshfield Medical Center-EC Cancer Center||Eau Claire||Wisconsin||United States||54701|
|334||Aurora Health Care Germantown Health Center||Germantown||Wisconsin||United States||53022|
|335||Aurora Cancer Care-Grafton||Grafton||Wisconsin||United States||53024|
|336||Aurora BayCare Medical Center||Green Bay||Wisconsin||United States||54311|
|337||Aurora Cancer Care-Kenosha South||Kenosha||Wisconsin||United States||53142|
|338||University of Wisconsin Carbone Cancer Center||Madison||Wisconsin||United States||53792|
|339||Aurora Bay Area Medical Group-Marinette||Marinette||Wisconsin||United States||54143|
|340||Marshfield Medical Center-Marshfield||Marshfield||Wisconsin||United States||54449|
|341||Aurora Cancer Care-Milwaukee||Milwaukee||Wisconsin||United States||53209|
|342||Aurora Saint Luke's Medical Center||Milwaukee||Wisconsin||United States||53215|
|343||Aurora Sinai Medical Center||Milwaukee||Wisconsin||United States||53233|
|344||Marshfield Clinic-Minocqua Center||Minocqua||Wisconsin||United States||54548|
|345||ProHealth Oconomowoc Memorial Hospital||Oconomowoc||Wisconsin||United States||53066|
|346||Vince Lombardi Cancer Clinic - Oshkosh||Oshkosh||Wisconsin||United States||54904|
|347||Aurora Cancer Care-Racine||Racine||Wisconsin||United States||53406|
|348||Marshfield Medical Center-Rice Lake||Rice Lake||Wisconsin||United States||54868|
|349||Vince Lombardi Cancer Clinic-Sheboygan||Sheboygan||Wisconsin||United States||53081|
|350||Marshfield Medical Center-River Region at Stevens Point||Stevens Point||Wisconsin||United States||54482|
|351||Aurora Medical Center in Summit||Summit||Wisconsin||United States||53066|
|352||Vince Lombardi Cancer Clinic-Two Rivers||Two Rivers||Wisconsin||United States||54241|
|353||UW Cancer Center at ProHealth Care||Waukesha||Wisconsin||United States||53188|
|354||Aurora Cancer Care-Milwaukee West||Wauwatosa||Wisconsin||United States||53226|
|355||Aurora West Allis Medical Center||West Allis||Wisconsin||United States||53227|
|356||Marshfield Medical Center - Weston||Weston||Wisconsin||United States||54476|
|357||The Moncton Hospital||Moncton||New Brunswick||Canada||E1C 6Z8|
|358||Royal Victoria Regional Health Centre||Barrie||Ontario||Canada||L4M 6M2|
|359||Juravinski Cancer Centre at Hamilton Health Sciences||Hamilton||Ontario||Canada||L8V 5C2|
|360||Kingston Health Sciences Centre||Kingston||Ontario||Canada||K7L 2V7|
|361||London Regional Cancer Program||London||Ontario||Canada||N6A 4L6|
|362||Lakeridge Health Oshawa||Oshawa||Ontario||Canada||L1G 2B9|
|363||Algoma District Cancer Program Sault Area Hospital||Sault Ste Marie||Ontario||Canada||P6B 0A8|
|364||Health Sciences North||Sudbury||Ontario||Canada||P3E 5J1|
|365||Odette Cancer Centre- Sunnybrook Health Sciences Centre||Toronto||Ontario||Canada||M4N 3M5|
|366||University Health Network-Princess Margaret Hospital||Toronto||Ontario||Canada||M5G 2M9|
|367||Hopital de la Cite-de-la-Sante||Laval||Quebec||Canada||H7M 3L9|
|368||CHUM - Centre Hospitalier de l'Universite de Montreal||Montreal||Quebec||Canada||H2X 3E4|
|369||Allan Blair Cancer Centre||Regina||Saskatchewan||Canada||S4T 7T1|
|370||Ehime University Hospital||Toon||Ehime||Japan||791-0295|
|371||Kure National Hospital||Kure||Hiroshima||Japan||737|
|372||Saitama Medical University International Medical Center||Saitama||Japan||350-1298|
|373||Keimyung University-Dongsan Medical Center||Dalseo-gu||Daegu||Korea, Republic of||42601|
|374||Samsung Changwon Hospital||Seoul||Gyeongsangnam-do||Korea, Republic of||51353|
|375||Gangnam Severance Hospital||Seoul||Korea, Republic of||06273|
|376||Korea Cancer Center Hospital||Seoul||Korea, Republic of||139-706|
|377||Centro Comprensivo de Cancer de UPR||San Juan||Puerto Rico||00927|
Sponsors and Collaborators
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
- NRG Oncology
- Principal Investigator: Ramez N Eskander, NRG Oncology
Study Documents (Full-Text)None provided.